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w. This stiy cvpluatcd the role d cha~~a in beart 
a& a* hllii pmsms rad ardbc tissue alrial rud brain 
urbretk pepUdts in the modulalioa of their plasma levels in a 
model d kah faibrt. 
&&gnu&, Atrial and brain natriuretic peptides constitute a 
dual utriomtie pcptklt system tbr( rqnlates circulator bo- 
tmta6ws. 
MW. Tile rleets d 1) acute vtallictlbr pack& 2) acmte 
volmne expausbn, and 3) volume expansion after I week of 
coatinmus pacing m pbsam rtrial and brain aatriuretic peptkle 
levels M campred ia eight dogs. Atrial and ventrkulrr tissue 
I& of the peptides wew nrmintd in S normal aogS (cootrot 
gorp),21dogpnd~innL(grwpl~~ndlo~pD~for 
3 mcks (gmP 2). 
&a&s. Bdh rcllC pmcbg ml vnbmc cxpamiou incrused 
pbxma rtIid Ilmimmtic peptidt kvds eom 53 f 41 to 263 f 
143 pg/al jwa 2 SD]. p < 0.01, 4 fmo 38 A 2.3 to 405 f 
221 pg/rl p c UOI. reqwively). After I wee4 there was a 
markulilrreuc ia plasma levels of strbl oatriuretic peptide. but 
tkkveldldaocim-mxe further titb vdome cxpaosion (from 
535 f I44 to 448 f I40 p%mI, p = 0.72). By contrast. plasma 
-_ 
Atria! and brain natriurctic peptides conrtitute a dual vasoac- 
tive natriuretic peptide system that has been implicated in 
circulatory homcostasis (l-8). Plasma levels of both peptides 
are elevated in hearr failure (Y-12). which suggests that they 
may play a regulatory role by counteracting the actions of the 
vasoconstrictor antidiuretic neurohotmones. 
Chronic rapid ventricular pacing induces severe heart fail- 
ure in dogs (I-q-16). Using this model, we previously reported 
(17-19) that plasma atrial natriuretic peptide levels pcakcd 
early but faikd IO incrcasc further during evolving heart failure 
despite continuing incrcae ir. atrial pressures and dimen- 
- 
brain natrioretic peptide krrl~ increased only modestly with acute 
pipe tfr0lD 12 f 4 to 20 2 8 p%ml, p c 0.05) and dt6f phg 
f~I~k(fmm13~4toUIf#Ip%nrl,p~O.Q5)ktdidsot 
change with rcute or rrpea~ rdume expansion. la groups I and 2, 
atrial tissue levels of atrial oawiuretir eide (1.9 + 1.3 and 
2.0 + 0.9 drng Rspertivety) ww lower than tha6e in the contml 
group (II.7 * 6.8 r#img. both p c 0.001). whereas vmnlricolrr 
levels we’ve similar to those in the coatml group. Atrial tissue 
brain natriuretic peptide kvels in groups 1 and 2 wew similar to 
those in the control gmup. However, vmtricular levels in grwp 2 
(fkOl8 f 0.006 aghgt wtrt increased compared with lbose in tbe 
control group (0.013 f 0.006 q/a& p < 0.05) nod in gmup I 
(0.011 * 0.006 ng/l& p c 0.05). 
C’o&uimu. Atrial and brain st:rioretk pepUdex rexpa& 
ditertntly to changes iu brart mtc and atrial pressures. Rtd& 
atrial tissw atrlal natriuretic peptide k&x in heati failure may 
indicate reduced storage db3 cnhsmd ardiic rek8se However, 
1% fvbtivrly modesI change ia cardbc tisspc bwaio natriwetic 
pepaIde levels sLt&#srs that tbe ckvrted plasma levels may he 
mediated by mchanisms other thao inweased atrial pressures. 
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sions. WC subsequently dcmonstratcd (20) that increased heart 
rate and atria1 pressures contributed 10 the increase in plasma 
atrial natriurctic pcptide levels, and hy I week of pacing. there 
was a blunted rcsponsc to volume expansion. Recently. we 
reported (2 1) that changes in plasma hrain natriuretic pcptide 
Ic~cls followed a similar time courstz to atrial natriuretic 
peptide levels. However. the magnitude of increase was smaller 
than that of atrial natriuretic peptide (21). This smaller 
increase in plasma brain natriuretic peptidc levels in response 
IO a similar increase in atrial pressure raises the question as to 
whether the mechanisms for the increased plasma levels of the 
two peptides may differ. 
Unlike atrial natriuretic peptide. the regulation of hrain 
natriuretic peptide in vivo has not been studied in detail. The 
questions to be addressed. therefore. are whether the regula- 
tion of these two p-ptidcs is different and whether thry change 
over time as heart failun? evolves. A knowledge of the acute 
and chronic effects of increases in heart rate and atria1 
pressures on plasma and cardiac tissue brain ratriuretic pep- 
tide levels might address this question and provide insight into 
its potential role in heart failure. In the current study we used 
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a protocol similar to one we previously used to study atria1 
natriurctic peptide (19). Our objectives were 1) to compare the 
responses of atrial and brain natriuretic peptide: to a) acute 
rapid right ventricular pacing, b) acute volume expansion, and 
c) repeat acute volume expansion after I week of continuous 
ventricular pacing: and 2) to compare regional cardiac tissue 
atrial and brain natriuretic peptide levels in normal dogs and 
dogs with early and advanced heart failure. 
Methods 
laductba of heart failure. The method of induction of 
heart failure has previously been described (15.20). Under 
general anesthesia. a pacing lead was advanced though the 
jugular vein to the right ventricular apex. and a programmable 
pulse generator (Medtronic SX-5985, MedtronL Canada) was 
inserted into a cervical pocket. An indwelling cannula was 
positioned in the aorta through the carotid artery. The dogs 
recovered from anesthesia for 1 week hefore the initial study. 
Thereafter. pacing (250 beats/min) was maintained either fnr I 
week (early heart failure [group I]) or for 3 weeis (severe 
heart failure [group 21). 
Response to volume expaasioa and wing. To assess the 
impact of acute versus chronic increases in heart rate and atrial 
pressures on plasma atrial and brdin natriurctic peptide kwls. 
eight dogs from group I underwent the three sequential 
protocols over the l-week period. 
Rotord A (nqmse to acute tempaty paring). On day I. 
the pacer was programmed to a rate of 250 beats/min for 
M min. Anerial blood samples for plasma atria1 and brain 
natriuretic peptide and norepinephrinr levels were obtained at 
baseline and IS and 30 min after pacing. The pacer was then 
reprogrammed to allow resumption of sinus rhythm. 
hwocd B (conml acute ~ohne apansion). On day 2 dogs 
were instrumented with a balloon-tipped thennodilution cath- 
etcr introduced through the right femoral vein, using lidocaine 
local anesthesia. After baseline hcmodynamic and echocardio- 
graphic measures and blood samples for the natriuretic pep 
tide and norepinephrine assay had been obtained. an infusion 
of 6% dextran was started at 35 mllmin. Physiologic measure- 
ments and blood samples were obtained every IO min for the 
next 30 min: The aim was to increase pulmonary capillary 
wedge pressure by -221) mm Hg. When the target was reached. 
the infusion was stopped, and the pacer was activated at 2.50 
beats/min. Measurements were repeated at I5 and 3(! min after 
the initiation of pacing. Pacing was maintained for I week. 
iktord C (repeat dwnc apnsion afier ! wk of pacmq). 
On day 8. the volume expansion study was repeated. Pacing 
was temporarily ceased for I5 min to obtain sinus rhythm 
physiologic variables characterizing the heati failure slate. 
After these measurements. pacing was resumed. and the 
volume expansion study was performed during pacing to 
maintain a steady state condition. The dextran was infused at 
the same rate as in day 2. Data were obtained every 5 min 
because it was anticipated that the target filling pressure would 
be reached earlier than at baseline. After the volume expan- 
sion. the dops recovered ior 24 h to allow the effects of volume 
expansion to dissipate. During thi\ time. pacing was main- 
tained. The dogs wcrc then killed on the next day for tissue 
studies. 
Cardiac dimcnsioas and plasma and cardiac tissue atil 
awl brain natri~rttic pc~idt his. Cardiac tissue for the 
measurements of atrial and brain natriurctic peptide levels 
were obtained from three groups of rbgs. Group I dogs (n = 
21) were pared for I week, and 8 of thev 21 dogs were those 
that underwent the phy%ologic studies described before, 
Group 2 dogs (n = IO) were paced for 3 weeks to severe heart 
failure. Severe heart failure was defined as a ~25Q increase in 
radiographic planimrtercd heart size. with pulmonary edema 
or ?lW increase in body weight. or both, as reported 
previously (15.17.18.21). Five normal dogs served as the con- 
trol group. 
All paced dogs underwent hemodynamic-echocardio- 
graphic studies 24 h hefore euthanasia. Left bcntricular volume 
was calculated at end-diastole as follows: (s/L)*Area 
Length. where Area = the planimetered cross-sectional area 
obtained from the short-axis vieu at the level of the papillary 
muscle. and Length = the length of the left ventricle obtained 
from the apical four-chamber view (19). Left r*rial volume was 
derived as follows: (3/4)+ArcaIength. where Area = the 
cross-sectional area obtained from the short-axis view at the 
level of the aortic valve, and Length = the length of the ieft 
atrium from the apical four-chamber view (20). At sacrifice. 
the animals were anesthetized with sodium thiopental, and a 
thoracotomy was performed. The heart was removed. trimmed 
and weig!!d. The body and appendage of each atrium. the 
interatrial septum as well as the free walls and septum nf the 
left and right ventricles were taken and immerserl in liquid 
nitrogen. Samples were stored at -fUPC. Tissue was homoge- 
nized with a Virtisckr (Virtis Inc.) in 0.1 molfliter acetic aciu 
and ccntrifugcd at 3WNW rpm. ?he pellet was discarded. and 
the supematant was stored at -2O’C (20). Plasma and tissue 
airial and brain natriuretic peptide levels were determined by 
rzdioimmunoassay using a commercial kit (Peninsula Labora- 
tories) and methods reported previously (21.2324). Plasma 
norepinephrine levels were determined by high performance 
liquid chromatography ( 18). 
%atis&l ana@is Changes over time were measured by 
:epeated-measure analysis of variance followed by Dunnett’s 
test. Comparisons between groups were made hy one-way 
analysis of variance followed hy Dunnett’s test using the 
statistical package MINIT.ti (Keleasc 7 Standard Version. 
Minitab Inc.). Relations between study variables were assessed 
hy linear repion analysis. Results are presented as mean 
value z SD. and p < U.05 waz considered significant. 
Results 
After I week of continuous pacing. the dogs developed 
moderately severe heart failure. Phpiologic data obtained at 
baseline and after I week of pacing and during temporary 
rcz.umption of sinus rhythm for 15 min arc shown in Table I. 
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T&k 1. Hcmodynamic and Echfxardiograpkic Variahk 31 Baseline and Mcr I Wrek of Pacing 
HR RAP PCWP LVEDP MAP (‘0 - I.bV 
Heart failure was characterized by increaseti cardiac filling 
pressures and left ventricular diastolic volume and reduced 
mean arterial pressure and cardiac output. 
Response to pacing oad volumt expansion. Changes in 
hemodynamic variables and left atrial volume in rcsponx to 
acute pacing and volume expansion are summarized in Tahlc 2. 
Changes in plasma atrial and brain natriurctic peptide and 
norepinephrine levels are shown in Table 3. On day I, acute 
ventricular pacing was as,wciatcd with a fivefold incrcasc in 
plasma atrial natriurctic pcptide levels at IS min that persisted 
at 30 min (Table 3). In contrast to atrial natriurctic peptide, 
there was only a moderate l.5-fold increase in plasma brain 
natriuretic peptide levels at .3O min. 
On day 2. volume expansion was asjociatcd with a striking 
increase in heart rate, cardiac output. lett- and right-sided 
cardiac filling pressures and left atrial volume (Table 2). 
Fifteen minutes after the pacer was turned on. there was no 
change in filling pressures. but cardiac output declined by 507 
from the values at peak volume expansion. By 31) min. cardiac 
filling pressures declined slightly from peak volume expansion. 
With volume expansion, plasma atrial natriuretic pptide levels 
incrcascd marl: than tenfold (Table 3). When pacing was 
initiated. there was a trend for an increase in plasma levels. but 
this was not statistically higniticant. By contrast. there was no 
change in plasma brain natriurctic pepride levels during vol- 
ume expansion despite the marked increase in cardiac filling 
pressures and in left atrial volume. With volume expansion. 
plasma norepincphrinc levels decreased at peak volume cx- 
p:msion hut returned to hasclinc at 30 min after pacing. 
On day X, after I week of pacing. cardiac filling pressures 
were markedly elrvatcd compared with those at baseline 
(Table 1). With volume expansion (Table 2). there was a 
further increase in filling pressures. The extent of increase 
induced by the repeat volume expansion was similar to that on 
&y 2. Left atrial volum:: also increased. Unlike day 2 volume 
cxpansiou did not increase cardiac output. As sl~own in Table 
3. baseline IevA of both peptides were elevated at I week 
compared with them at days I and 2. The magnitude of 
increax in baseline hrain natriuretic pcptide was srr.aller than 
that for atrial natriuretic peptide. Unlike day 2. at I week there 
was no ftirthcr increase in plasma atrial natriuretic peptide 
after volume expansion. Plasma brain natriurctic peptidc levels 
Table 2. Efferts of Pacing and Volume Expansion cm Hurwdyamic Variahlcr 
Ti HR RAP KWP LVEDP MAP co IAV 
(min) (hcab’min ) (mm HI!) (mm HI!) (mm Hg) (mm W (lilun min) (cm’1 
Tibk 3. Plllima Natriurctic Peptide and Norepinephrtno Lcwls 
Time A?lP WP NE 
(mini fmml) (p&ml1 fwmll 
II 535 2 IU 4x.4 f 3.5 s3t ?>I 
s 411 ! li l 3Y.Y ? 10.7 
10 474 ! In Mt.4 2 3J.S 
IT 4.w Y ?lY J2.I : 1b.h UI t IV4 
‘p < 11.111, tp < lI.ofi ww hdinc ((I min) for each prcrmd. Rnultx nor 
day 8 wcrc &air& rlth pacing mamtaincd Data pmntcd arc mean ~aluc f 
SD. AHP = atria1 nalriurctic pcptidc: BNP = twain ~~riuretr pcpt~du: fG;E = 
norcpincphrinc: dtcr ahfvcviathm as in Tahk 2. 
also did not change despite the further increax in filling 
pressures. and plasma norepinephrine levels remained unal- 
tered. 
Hart wtigbts and plasma 8ad cardiac tissoc rtil and 
brain natriuretic peptidc ltvtls. Data for cardiac filling pres- 
sures, heart weights, plasma and cardiac tissue natriuretic 
peptide levels in the control dogs and dogs paced for 1 week 
(group I) ah-d 3 weeks (group 2) are shown in Table 4. Cardiac 
filling pressurl? were much higher :n group 2 than group I, 
indicating more advanced heart failure. There are no differ- 
ences in heart weighi5 among the three study groups. 
Atria/ nafriu~ric pppriot. Plasma atrial natriuretic peptide 
levels in groups 1 and 2 were significantly higher than those in 
the control group (p < 0.01). In the control dogs, there were 
significant intraarterial and interatrial regional differences 
(p = 0.05. analysis of variance) in tissue peptide levels. The 
levels were higher in the appendages than the free walls and 
higher in the left than the right atria. Tissue levels in the 
ventricles were lower than those in the atria. and there were no 
significant regional variations. In group 1 and 2 dogs, atrial 
tissue levels were lower than those in control animak in all 
regions, and there were no significant intraalrial or interatria 
regional differences. As shown in Figure I& the average levels 
of the four atrial regions were lower in groups I and 2 than in 
the control group. Tissue levels in the left ventricular ftee wall 
and interventricular septum were similar to those of control 
dogs but the lever was lower than in controt * in the righhr 
ventricular free wall (both p < 0.05 vs. control dogs). As shown 
in Figure IA. the average ventricular atrial natriuretic peptide 
levek of the left and right ventricles and the inrerventricular 
septum were similar in the three groups. In all regions. Ihcre 
wrte no corrdations between cardiac filling prmures and 
tissue atrial natriuretic peptide Ievclc. 
&in na!tiuntic peprirle. Plasma brain natriuretic peptide 
levels in group+ 1 and 2 were significantly higher than those in 
the control group (p < 0.01). In the control group. there were 
no intraatrial regional dikrences (p = 0.43). Like atrial 
natriuretic peptide. brain natriuretic peptide levels were lower 
in the ventricle than in the atrium in all three groups. In group 
2. atrial tissue brain natriuretic peptide levels tended to be 
higher than those in the control dogs. although the difference 
was significant in the left atrial free wall only. The mean tissue 
brain natriuretic levels from the atrial sites are shown in Figure 
I B. There was a trend for atrial levels to be higher in groups 1 
and 2 than in the con:rol group, but the differences were not 
significant (p = 0.14). Brain natriuretic peptide levels in the 
left ventricular free wall were similar in all three groups. but in 
grnup 2 the levels in the septum and right ventricular free wall 
were elevated. The mean levels of brain natriuretic peptide in 
the three ventricular regions are depicted in Figure IB. Mean 
ventricular levels in group 2 were higher than those in group I. 
There were no conelations between filling pressures and tissue 
brain natriurctic peptide levels. 
Discussion 
Our study provides n,w information regarding I) the effects 
of acute versus chronic increases in heart rate, atrial pressures 
and left alrial volume on plasma and brain natriuretic peptide 
levels: and 3) regional ctirdiac tissue natriuretic peptide levek 
in the atria and ventricles of normal dogs and dogs with early 
and severe heart failure. 
E&tsoracottm4cbnmiciKmstsinbmrlntt,ntrtl 
pmsons and vohmr. Both acute pacing and volume expan- 
sion increase plasma alrial natriuretic peplidc Icyels. * 
findings are consistent with our previous reports showing that 
rhe increase in plasma atria1 natriuretic peptide levek induced 
by acute pacing (18.20) and acute volume expansion (19) is 
mediated by an incrtxu in cardiac filling pressure and left 
atrial volume. After 1 week, atrial pressures and Wlume and 
atrial nattiuretic peptide levels are all increased. Although 
volume expansion after I week of pacing produces further 
increases in atria1 pressures and volume. there was M further 
increase in plasma atrial natriurelic peptide levels. The plasma 
level achieved during volume expansion at I week is compa- 
rable IO maximal values obtained after volume expansion and 
pacing at day 2. Therefore, our observations indicate that 
rhe release of atrial natriuretic pepide is attenuated after the 
development of hean failure because there is a limit to the 
increase in plasma levels during acute and chronic increases in 
atrial pressures and heart fate (19). 
To our knowledge. the present study is the first to compare 
the response of atrial and brain natriuretic peptides with acute 
and chronic increases in heart rate and atria1 pressurn The 
two pep&es responded differenlly. Whereas acute pacing 
produced a l&fold increase in plasma atrial nalriurelic peptide 
NATRlURETlC PEPTIDES IFi WART FAILLJRI: 
T* 4. Cardiac Filling Pressure> and Plasma and CarJiao Tissue Alr~al and &in Naburrtic 
Pcptidc Levels - 
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*Anna&i nf wnanm Data prcwnrcd arc mean vuluc + SD Group I = p;rccd frlr I ucck 161 early heart failure: group 
2 = paced fnr 3 web 141 wvcrc hcsrl fadurc: IIW = hcdr! wlght: LAA = lrft &Ul :yqwxlagc. LVFM’ kfi ucn~riculur 
free wall: RA - rlghl ab-ium: RAA - right slrhl appcndqc; RVFW = ryht wntricul~r frcr wall. mhcr ahhwrations 
ar in Tahhlcr I and 3. 
levels, it induced only a 1.5~fold increase in plasma brain 
natriuretic peptide levels. Such a modest increase in the latter 
plasma levels has been observed in patients with supraventric- 
ular tachyarrhythmias (U). On day 2, although volume cxpan- 
sion followed by pacing produced a marked increase in cardiac 
filling pressures and left atrial Aume. plasma brain natriuretic 
peptide levels did not alter. After I week of pacing. plasma 
levels increased fourfold, still less than the tenfold increase 
observed in atrial natriuretic peptide levels. With rcpcat 
volume expansion, there was no further increase in plasma 
natriuretic peptide levels despite a further increase in atria1 
pressures and left atrial volume. These findings may account 
for the smaller increase in plasma brain versus atrial natriuretic 
peptide levels that we observed previously during evoking 
heart failure (20). Coupling this finding with our previous 
report that after cessation of pacing, plasma brain natriuretic 
peptide levels dectined at a slower rate than atrial natriurctic 
peptide levels, the data indicate that the former is a les finely 
regulated system. Studies m rat atrial cells have suggested (26) 
that the regulation of the synthesii and release of the two 
peptides arc different. Therefore. although brain natriuretic 
pcptidc is less responsive than atrial natriuretic pcptide to 
acute changes in heart rate and atrial pressures, the system 
appears to respond to chronic increases in heart rate and atrial 
pressures. suggesting tha: it may be involved in the more 
long-term rthgulation of blood pressure and volume, whereas 
atrial natriuretic peptide regulates short-term changes. 
Plasma norepincphrine Icvels increased after acute pacieg. 
This increase may reflect a reflex-mediated increase in sympa- 
thetic nerve activity in respon= to an abrupt decline in stroke 
volume. The decline in plasma norepinephrinc levels after 
volume expansion on day 2 may reflect inhibition of sympa- 
thetic outflow through stimulation of the cardiopulmonary 
reflex (27.28). The lack of a change in plasma norepinephrine 
levels after volume expansion after I week of pacing most 
likety indicates blunting of the cardiopulmonary reflex, consis- 
tent with our recent report that attenuation of the cardiopul- 
monary barorcflex OCCUR within 1 wtiek of pacing (29). 
m tbsuc araiorttie pepMe kvds. The cardiac tis- 
sue natriuretic peptide data provide insights into the me&- 
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F@t I. Mean tissue atrial natriuretic pcptidc (ANP) (Al ;.nJ brain 
natriuretic vptidc (BNP) levels fB) from !hc atria lapper pun4 and 
vcniriclcs Oower panel). Control = mlrmat w Mid bars): Early 
CHF = group I dogs with early hcvti failure (open brrs) Scvcrc 
CHF = group 2 dog wilh severe heart failure (blcbt4 blls). 
Prohahilit~ vrluc~ arc frc.a analysis of vanancc. 
nisms of increased plasma natriurctic peptide levels ie heart 
failure. In normal dogs, the atrial appendages have the :lig.hest 
atria! natriuretic pcptide levels. sugesting that the appendages 
act as a depot site. Ventricular levels are much Iowcr. and 
there is no regional variation, suggesting that the ventricles are 
not the primary site of synthesis. In dogs with heart ‘ailure. 
atrial levels are markedly reduced. These tindings of reduced 
atrial natriuretic pcptide levels in the atria arc similar to 
previous reports in w with pacing-induced heart failure. 
myopathic hamsters and rats with coronary artery ligat on> as 
well as humans with heart failure (20.30-X). In contrast. a 
study in humans with heart failure reported increased atrial 
natriuretic peptide levels in the left atrium (33). That study 
also reported a marked increase in the beta-form (56 amino 
acid antiparallel dimer of the alpha-form) and the prohormonc 
in the atrial appendages. Notwithstanding the limitations of 
comparing data from different species and models, the data on 
Ventricles 
halance suggest that in heart failure thcrc is enhanced release 
of the peptide. 
Whether atrial tissue storage is reduced or not will depend 
on the chronic@ and severity of tnc disease, the species choxn 
for study. the method of quantification of the peptides or the 
choice of sampling site. In our study. tis,ur levels in the leh 
ventricle and the -plum were similar in the three groups. The 
reason for the small reduction in levels in the right ventricle in 
dogs with advanced heart failure is unclear. II may rslate in 
part to the effect of pacing. In other models of heart failure. 
ventricular tissue atrial natriuretic peptide levels have been 
shown to be higher than thou in normal control animals 
(34.35). In czmtrast. studio in humans with heart failure report 
no change (23). Of note is thr consistent report of increased 
atrial natriuretic peptide mRNA levels in the failing ventricles 
(36.37). Ventricular synthesis of the peptide is most likely 
activated in heart failure, but a constitutive type of rekase of 
the peptide in the ventrrles (-34) might account for the 
increases in atrial natriurrtic peptide mRNA levels out of 
proputlion to the tissue Icvels. 
Plasma brain natriuretic pcptidc levels in dogs with early 
and advanced heart failure arc increased to a similar cxtrnl to 
those in control c@. These data are consistent with our 
previous sequential dxervations of a plateruing of tfk! plasma 
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level after I week of pacing (20). In normal dogs. the atrio- to head-down tilt is blunted. Our conclusion of increased 
ventricular ratio (l&l) is smaller than that for atrial nstriuretic ventricular production of hrain natriuretic peptide is limited by 
peptide (4CKI:l). In dogs with early and advanced heart failure, the fact that we did not formaRy assess its production and 
there is a trend for atrial tissue levels to be higher. hut the secretion. Howcvcr, studies in patients with hean fai!Jre have 
difference is significant only for the left atrial free wall. In suggested that there is increased ventricular production of 
normal rats, 60% of cardiac brain natriuretic peptide comes both peptides (12.45). 
from the ventricle compared with only 5% of atrial natriuretic Conclusions. Atrial and brain natriuretic peptidrs consti- 
peptide (39). In hypertensive rats. ventricular brain natriuretic tutu a dual natriuretic peptide system, both components of 
peptide levels and secretion are markedly increased (40). which arc activated in heati failure. However, the mechanisms 
IIssue immunoxactive brain natriurctic peptide levels in the for increase plasma levels for the two peptides appear to be 
atrium and immunohistochemical staining for the pcptide in different. Increawd atrial pressures most likely play iess of a 
the ventride are both increased in patients with heart failure Cole in brain than that supposed for atrial natriuretic peptide. 
compared with the donors (32). These data suggest there is The two peptides may therefore play different regulatory roles 
enhanced cardiac production of thij peptide in heart failure. In in heart failure. 
our dogs with advanced heart failure, there was only a modest 
increase in ventricular brain natriuretic peptide levels. Al- - 
though different preparations and techniques may account for 
WC thank Mary JO SlcDon~ld. Cccrrgr Naik. Andrea Konip and Bonnie WI&! 
for tc.rhni:dl JMI~CC dnd Mcdtronic Canada k,rthr wpply ofpulu gcncrators 
the discrepancy among studies. the data on halance suggest 
that relative to atria1 natriuretic peptide, the ventricle assumes 
a more important role than the atrium in the synthesis of brain 
natriuretic peptide. 
It is useful to examine the tissue brain natriuretic peptidc 
data in conjunction with the plasma data and their response to 
pacing and volume expansion. The lack of a response to acute 
volume expansion despite the marked increase in cardiac filling 
pressures indicates that brain natriuretic peptide is not sensi- 
tive to acute increases in cardiac filling prmures. In contrast. 
the increax in plasma level after 1 week of pacing was induced 
by only a modest rise in atrial pressures. Indeed, the degree of 
elevation in wedge pressure after 1 week ws similar to that 
achieved after IO min of volume expansion, when there was no 
and paonp luth. 
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